Patents by Inventor Jay P. Barbor

Jay P. Barbor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
    Publication number: 20230109833
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 13, 2023
    Applicants: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents
    Patent number: 11505533
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: November 22, 2022
    Assignees: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • Broad spectrum inhibitors of filoviruses
    Patent number: 11459308
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: October 4, 2022
    Assignees: Microbiotix, Inc., Albert Einstein College of Medicine, The Government of the United States as Represented by the Secretary of the Army
    Inventors: Terry L. Bowlin, Donald T. Moir, Kartik Chandran, John M. Dye, Jr., John D. Williams, Zachary D. Aron, Jay P. Barbor, Kelly N. Lively, Peter J. Nash, Debra M. Mills, Arnab Basu
  • METABOLICALLY STABLE N-ACYLAMINOOXADIAZOLES USEFUL AS ANTIBACTERIAL AGENTS
    Publication number: 20200361882
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of bacterial infections in humans and other mammals. A new class of small molecules is disclosed that inhibits the bacterial trans-translation/ribosome rescue mechanism and thus blocks infection of host cells by bacteria. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of bacterial infections.
    Type: Application
    Filed: August 21, 2018
    Publication date: November 19, 2020
    Applicants: MICROBIOTIX, INC., THE PENN STATE RESEARCH FOUNDATION
    Inventors: Zachary D. Aron, Steven M. Kwasny, Matthew C. Torhan, Jay P. Barbor, Steven C. Cardinale, Michelle M. Butler, Timothy J. Opperman, Kenneth C. Keiler
  • BROAD SPECTRUM INHIBITORS OF FILOVIRUSES
    Publication number: 20190292165
    Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.
    Type: Application
    Filed: December 5, 2017
    Publication date: September 26, 2019
    Applicants: Microbiotix, Inc., Albert Einstein College Of Medicine, Inc., The Govermnment Of The United States As Represented By The Secretary Of The Army
    Inventors: Terry L. Bowlin, Donald T. Moir, Kartik Chandran, John M. Dye, John D. Williams, Zachary D. Aron, Jay P. Barbor, Kelly N. Lively, Peter J. Nash, Debra M. Mills, Arnab Basu